A Novel Serum Marker, Total Prostate Secretory Protein of 94 Amino Acids, Improves Prostate Cancer Detection and Helps Identify High Grade Cancers at Diagnosis

Nam, Robert K.; Reeves, Jonathan R.; Toi, Ants; Dulude, Hélène; Trachtenberg, John; Emami, Marjan; Daigneault, Luc; Panchal, Chandra J.; Sugar, Linda; Jewett, Michael A.S.; Narod, Steven A.

doi:10.1016/s0022-5347(05)00695-6

Cited by 62 publications

(62 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bound forms of PSP94 exist as a complex with PSP94-binding protein. Serum concentrations of the ratio of PSP94 to free PSP94 and serum concentrations of PSP94-binding protein in CaP patients after local surgery were associated with Gleason sum, biochemical recurrence, and surgical margin status (52 ). Large prospective studies are still required to validate this candidate biomarker.…”

Section: Prostate Secretory Protein 94 and Binding Proteinmentioning

confidence: 99%

Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer

2008

View full text Add to dashboard Cite

Background: Early detection of prostate cancer (CaP), the most prevalent cancer and the second-leading cause of death in men, has proved difficult, and current detection methods are inadequate. Prostate-specific antigen (PSA) testing is a significant advance for early diagnosis of patients with CaP. Content: PSA is produced almost exclusively in the prostate, and abnormalities of this organ are frequently associated with increased serum concentrations. Because of PSA’s lack of specificity for CaP, however, many patients undergo unnecessary biopsies or treatments for benign or latent tumors, respectively. Thus, a more specific method of CaP detection is required to augment or replace screening with PSA. The focus recently has been on creating cost-effective assays for circulating protein biomarkers in the blood, but because of the heterogeneity of CaP, it has become clear that this effort will be a formidable challenge. Each marker will require proper validation to ensure clinical utility. Although much work has been done on variations of the PSA test (i.e., velocity, density, free vs bound, proisoforms) with limited usefulness, there are many emerging markers at various stages of development that show some promise for CaP diagnosis. These markers include kallikrein-related peptidase 2 (KLK2), early prostate cancer antigen (EPCA), PCA3, hepsin, prostate stem cell antigen, and α-methylacyl-CoA racemase (AMACR). We review biomarkers under investigation for the early diagnosis and management of prostate cancer. Summary: It is hoped that the use of panels of markers can improve CaP diagnosis and prognosis and help predict the therapeutic response in CaP patients.

show abstract

Section: Prostate Secretory Protein 94 and Binding Proteinmentioning

confidence: 99%

Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer

2008

View full text Add to dashboard Cite

show abstract

“…[13][14][15] Serum levels of MSMB, its binding protein PSP94-binding protein (PSPBP) and the ratio free/bound MSMB, have all been suggested as independent prognostic factors in prostate cancer. [16][17][18][19] We have previously reported that the cysteine-rich secretory family (CRISP) family member CRISP3 also forms a high-affinity complex with MSMB in human seminal plasma. 20 CRISP3 has been found to be one of the most upregulated genes in prostate cancer compared to benign tissue, 21,22 and was proposed to be a useful biomarker for prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3

Dahlman

Edsjö

Halldén

et al. 2010

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

We have investigated the effects of short-term neoadjuvant and long-term androgen deprivation therapies (ADTs) on b-microseminoprotein (MSMB) and cysteine-rich secretory protein-3 (CRISP3) expression in prostate cancer patients. We also studied if MSMB expression was related to genotype and epigenetic silencing. Using an Affymetrix cDNA microarray analysis, we investigated the expression of MSMB, CRISP3, androgen receptor (AR), KLK3 and Enhancer of Zeste Homologue-2 (EZH2) in tissue from prostate cancer patients receiving (n ¼ 17) or not receiving (n ¼ 23) ADT before radical prostatectomy. MSMB, CRISP3 and AR were studied in tissue from the same patients undergoing TURP before and during ADT (n ¼ 16). MSMB genotyping of these patients was performed by TaqMan PCR. MSMB and KLK3 expression levels decreased during ADT. Expression levels of AR and CRISP3 were not affected by short-term ADT but were high in castration-resistant prostate cancer (CRPC) and metastases. Levels of EZH2 were also high in metastases, where MSMB was low. Genotyping of the MSMB rs10993994 polymorphism showed that the TT genotype conveys poor MSMB expression. MSMB expression is influenced by androgens, but also by genotype and epigenetic silencing. AR and CRISP3 expression are not influenced by short-term ADT, and high levels were found in CRPC and metastases.

show abstract

“…Two interacting prostate proteins, namely, the prostatic secretory protein of 94 amino acids (PSP94), encoded by the MSMB gene, and the cysteine-rich secretory protein CRISP-3, also known as SGP28, have been advanced as PCa biomarkers. [2][3][4][5] In parallel, much attention has gone to the functional characterization of these proteins. Pathak et al 6 now report in the Asian Journal of Andrology that both PSP94 and CRISP-3 function as growth inhibitors of subsets of PCa cell lines, despite their inversely correlated expression levels during PCa progression ( Figure 1a).…”

mentioning

confidence: 99%

Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3

Eynde¹,

Litovkin²

2010

Asian J Androl

View full text Add to dashboard Cite

A Novel Serum Marker, Total Prostate Secretory Protein of 94 Amino Acids, Improves Prostate Cancer Detection and Helps Identify High Grade Cancers at Diagnosis

Abstract: Patients with low total PSP94 levels had a high probability for having prostate cancer detected at biopsy. The total PSP94 level was able to help identify patients with high grade disease among a subset of patients in whom PSA and FTPSA are least informative.

Cited by 62 publications

References 18 publications

Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer

Emerging Biomarkers for the Diagnosis and Prognosis of Prostate Cancer

Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3

Growth inhibition properties of the putative prostate cancer biomarkers PSP94 and CRISP-3

Contact Info

Product

Resources

About